Entresto is a combination of a first-in-class neprilysin inhibitor and an angiotensin receptor blocker indicated for the treatment of heart failure with reduced ejection fraction.
Sylvester O. Agbahiwe PharmD, BCACP
Advertisement
Articles by Sylvester O. Agbahiwe PharmD, BCACP
Kcentra is the first nonactivated 4-factor prothrombin complex concentrate for the urgent reversal of acquired coagulation deficiency induced by vitamin K antagonist therapy.
Advertisement
Latest Updated Articles
- Kazano by Takeda Pharmaceuticals America, Inc
Published: February 17th 2014 | Updated:
EntrestoPublished: November 12th 2015 | Updated:
Kcentra by CSL BehringPublished: April 21st 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
3
High Non-HDL-C/HDL-C Ratio in Adults With Obesity Increases Depression Risk
4
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
5
